Around 4,500 people in the UK will be eligible for a new oral treatment for uterine fibroids. It follows the National Institute for Health and Care Excellence (NICE) recommendation of relugolix with estradiol and norethisterone acetate, also known as Ryeqo.
The oral treatment is made by Gedeon Richter UK and offers an alternative to surgery and injectable gonadotrophin-releasing hormone agonists…
